SEARCH

SEARCH BY CITATION

References

  • 1
    Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2003; 2: 34756.
  • 2
    Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol 2003; 2: 47381.
  • 3
    Patsalos PN, Froscher W, Pisani F, Van Rijn C. The importance of drug interactions in epilepsy therapy. Epilepsia 2002; 43: 36585.
  • 4
    Hachad H, Ragueneau-Majlessi I, Levy RH. New antiepileptic drugs: review on drug interactions. Ther Drug Monit 2002; 24: 91103.
  • 5
    Majkowski J, Bourgeois B, Patsalos PN, Mattson RH, eds. Antiepileptic Drugs: Combination Therapy and Interactions. Cambridge: Cambridge University Press 2005.
  • 6
    Perucca E, Hedges A, Makki KA, Ruprah M, Wilson JF, Richens A. A comparative study of the enzyme inducing properties of anticonvulsant drugs in epileptic patients. Br J Clin Pharmacol 1984; 18: 40110.
  • 7
    Strolin Benedetti M, Bani M. Metabolism-based interactions involving oral azole antifungals in humans. Drug Metab Rev 1999; 31: 665717.
  • 8
    Anderson GD. A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother 1998; 32: 55463.
  • 9
    Spina E, Perucca E, Levy RH. Predictability of metabolic antiepileptic drug interactions. In Antiepileptic Drugs: Combination Therapy and Interactions, eds MajkowskiJ, BourgeoisB, PatsalosPN, MattsonRH. Cambridge: Cambridge University Press 2005.
  • 10
    Perucca E. Clinical implications of hepatic microsomal enzyme induction by antiepileptic drugs. Pharmacol Ther 1987; 33: 13944.
  • 11
    Perucca E. The clinical pharmacology and therapeutic use of the new antiepileptic drugs. Fund Clin Pharmacol 2001; 15: 40517.
  • 12
    Crawford P. Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs 2002; 16: 26372.
  • 13
    Sidhu J, Bulsara S, Job S, Philipson R. A bidirectional pharmacokinetic interaction study of lamotrigine and the combined oral contraceptive pill in healthy subjects. Epilepsia 2004; 45 (Suppl. 7): 330.
  • 14
    May TW, Rambeck B, Jurgens U. Serum concentrations of lamotrigine in epileptic patients: the influence of dose and comedication. Ther Drug Monit 1996; 18: 52331.
  • 15
    Baruzzi A, Albani F, Riva R. Oxcarbazepine: pharmacokinetic interactions and their clinical relevance. Epilepsia 1994; 35 (Suppl. 3): S14S19.
  • 16
    Kim RB. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab Rev 2002; 34: 4754.
  • 17
    Synold TW, Dussault I, Forman BM. The orphan nuclear receptor SXR coordinatively regulates drug metabolism and efflux. Nat Med 2001; 7: 58490.
  • 18
    Giessmann T, May K, Modess C, Wegner D, Hecker U, Zschiesche M, Dazert P, Grube M, Schroeder E, Warzok R, Cascorbi I, Kroemer HK, Siegmund W. Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. Clin Pharmacol Ther 2004; 76: 192200.
  • 19
    Perucca E, Hebdige S, Frigo GM, Gatti G, Lecchini S, Crema A. Interaction between phenytoin and valproic acid: plasma protein binding and metabolic effects. Clin Pharmacol Ther 1980; 28: 77989.
  • 20
    Tsanaclis LM, Allen J, Perucca E, Routledge PA, Richens A. Effect of valproate on free plasma phenytoin concentrations. Br J Clin Pharmacol 1984; 18: 1720.
  • 21
    Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 2002; 71: 11521.
  • 22
    Perucca E, Levy RH. Combination therapy and drug interactions. In Antiepileptic Drugs, 5th edn, eds LevyRH, MattsonRH, MeldrumBS, PeruccaE. Philadelphia: Lippincott Williams & Wilkins 2002; 96102.
  • 23
    Perucca E, Gatti G, Frigo GM, Crema A, Calzetti S, Visintini D. Disposition of sodium valproate in epileptic patients. Br J Clin Pharmacol 1978; 5: 4959.
  • 24
    May T, Rambeck B. Serum concentrations of valproic acid: influence of dose and comedication. Ther Drug Monit 1985; 7: 38790.
  • 25
    Samara EE, Gustavson LE, El-Shourbagy T, Locke C, Granneman GR, Sommerville KW. Population analysis of the pharmacokinetics of tiagabine in patients with epilepsy. Epilepsia 1998; 39: 86873.
  • 26
    Giaccone M, Bartoli A, Gatti G, Marchiselli R, Pisani F, Latella MA, Perucca E. Effects of enzyme inducing anticonvulsants on ethosuximide pharmacokinetics in epileptic patients. Br J Clin Pharmacol 1996; 41: 5759.
  • 27
    Bartoli A, Guerrini R, Belmonte A, Alessandri MG, Gatti G, Perucca E. The influence of dosage, age, and comedication on steady state plasma lamotrigine concentrations in epileptic children: a prospective study with preliminary assessment of correlation with clinical response. Ther Drug Monit 1997; 19: 25260.
  • 28
    Armijo JA, Bravo J, Cuadrado A, Herranz JL. Lamotrigine serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and dosage implications. Ther Drug Monit 1999; 21: 18290.
  • 29
    Britzi M, Perucca E, Soback S, Levy RH, Fattore C, Crema F, Gatti G, Doose DR, Maryanoff BE, Bialer M. Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the presence and absence of enzyme induction by carbamazepine. Epilepsia 2005; 47: 17.
  • 30
    Tartara A, Galimberti CA, Manni R, Morini R, Limido G, Gatti G, Bartoli A, Strada G, Perucca E. The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxycarbazepine in normal subjects and in epileptic patients treated with phenobarbitone or valproic acid. Br J Clin Pharmacol 1993; 36: 3668.
  • 31
    Ojemann LM, Shastri RA, Wilenski AJ, Friel PN, Levy RH, McLean JR, Buchanan RA. Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patients on carbamazepine or phenytoin monotherapy. Ther Drug Monit 1986; 8: 2936.
  • 32
    Wagner M, Graves NM, Marineau K, Holmes GB, Remmel RP, Leppik IE. Discontinuation of phenytoin and carbamazepine in patients receiving felbamate. Epilepsia 1991; 32: 398406.
  • 33
    Khoo KC, Mendels J, Rothbert M, Garland WA, Colburn WA, Min BH, Lucek R, Carbone JJ, Boxenbaum HG, Kaplan SA. I nfluence of phenytoin and phenobarbital on the disposition of a single oral dose of clonazepam. Clin Pharmacol Ther 1980; 28: 36875.
  • 34
    Sennoune S, Mesdjian E, Bonneton J, Genton P, Dravet C, Roger J. Interactions between clobazam and standard antiepileptic drugs in patients with epilepsy. Ther Drug Monit 1992; 14: 26974.
  • 35
    Christiansen J, Dam M. Influence of phenobarbital and diphenylhydantoin on plasma carbamazepine levels in patients with epilepsy. Acta Neurol Scand 1973; 49: 5436.
  • 36
    Perucca E, Dulac O, Shorvon S, Tomson T. Harnessing the clinical potential of antiepileptic drug therapy: dosage optimisation. CNS Drugs 2001; 15: 60921.
  • 37
    Battino D, Croci D, Granata T, Bernardi G, Monza G. Changes in unbound and total valproic acid concentrations after replacement of carbamazepine with oxcarbazepine. Ther Drug Monit 1992; 14: 3769.
  • 38
    Yuen AWC, Land G, Weatherley B, Peck AW. Sodium valproate inhibits lamotrigine metabolism. Br J Clin Pharmacol 1992; 33: 5113.
  • 39
    Binnie CD, Van Emde Boas W, Kasteleijn Nolste Trenite DG, De Korte RA, Meijer JWA, Meinardi H, Miller AA, Overweg J, Peck AW, Van Wieringeen A, Yuen WC. Acute effects of lamotrigine (BW430C) in persons with epilepsy. Epilepsia 1986; 27: 24854.
  • 40
    Gidal BE, Anderson GD, Rutecki PR, Shaw R, Lanning A. Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy. Epilepsy Res 2000; 42: 2331.
  • 41
    Kapetanovic IM, Kupferberg HJ, Porter RJ, Theodore W, Schulman E, Penry JK. Mechanism of valproate–phenobarbital interaction in epileptic patients. Clin Pharmacol Ther 1981; 29: 4806.
  • 42
    Barcs G, Walker EB, Elger CE, Scaramelli A, Stefan H, Sturm Y, Moore A, Flesch G, Kramer L, D’Souza J. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia 2000; 41: 1597607.
  • 43
    Bialer M, Doose DR, Murthy B, Curtin C, Wang SS, Twyman RE, Schwabe S. Pharmacokinetic interactions of topiramate. Clin Pharmacokinet 2004; 12: 76380.
  • 44
    Pisani F, Fazio A, Oteri G, Ruello C, Gitto C, Russo F, Perucca E. Sodium valproate and valpromide: differential interactions with carbamazepine in epileptic patients. Epilepsia 1986; 27: 54852.
  • 45
    Pisani F, Oteri G, Russo MF, Di Perri R, Perucca E, Richens A. The efficacy of valproate–lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia 1999; 40: 11416.
  • 46
    Rowan AJ, Meijer JWA, De Beer-Pawlikowski N, Van Der Geest P, Meinardi H. Valproate–ethosuximide combination therapy for refractory absence seizures. Arch Neurol 1983; 40: 797802.
  • 47
    Besag FMC, Berry DJ, Pool F, Newbery JE, Subel B. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction? Epilepsia 1998; 39: 1837.
  • 48
    Sabers A, Ohman I, Christensen J, Tomson T. Oral contraceptives reduce lamotrigine plasma levels. Neurology 2003; 61: 5701.
  • 49
    Sabers A, Buchholt JM, Uldall P, Hansen EL. Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res 2001; 47: 1514.
  • 50
    Bauer LA. Interference of oral phenytoin absorption by continuous nasogastric feeding. Neurology 1982; 32: 5702.
  • 51
    Worden JP Jr, Wood CA Jr, Workman CH. Phenytoin and nasogastric feedings. Neurology 1984; 34: 132.
  • 52
    Vecht CJ, Wagner GL, Wilms EB. Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol 2003; 2: 4049.
  • 53
    De Turck BJ, Diltoer MW, Corneli PJ, Cornelis PJ, Maes V, Spapen HD, Camu F, Huyghens LP. Lowering of plasma valproic acid concentrations during concomitant therapy with meropenem and amikacin. J Antimicrob Chemother 1998; 42: 5634.
  • 54
    Sander JW, Perucca E. Epilepsy and comorbidity: infections and antimicrobials usage in relation to epilepsy management. Acta Neurol Scand 2003; 108 (Suppl. 180): 1622.
  • 55
    Von Moltke LL, Greenblatt DJ, Schmider J, Wright CE, Harmatz J, Schader RI. In vitro approaches to predicting drug interactions in vivo. Biochem Pharmacol 1998; 55: 11322.
  • 56
    Pauwels O. Factors contributing to carbamazepine–macrolide interactions. Pharmacol Res 2002; 45: 2918.
  • 57
    Van Rosensteil NA, Adam D. Macrolides antibacterials. Drug interactions of clinical significance. Drug Safety 1995; 13: 10522.
  • 58
    Ducharme MP, Slaughter RL, Warbasse LH, Chandrasekar PH, Van de Velde V, Mannens G, Edwards DJ. Itraconazole and hydroxyitraconazole serum concentrations are reduced more than ten-fold by phenytoin. Clin Pharmacol Ther 1995; 58: 61724.
  • 59
    Bittencourt PRM, Gracia CM, Martins R, Fernandes AG, Diekmann HW, Jung W. Phenytoin and carbamazepine decrease oral bioavailability or praziquantel. Neurology 1992; 42: 4926.
  • 60
    Romanelli F, Jennings HR, Nath A, Ryan M, Berger J. Therapeutic dilemma: the use of anticonvulsants in HIV-positive individuals. Neurology 2000; 54: 14047.
  • 61
    Hugen PW, Burger DM, Brinkman K, Ter Hofstede HJ, Schuurman R, Koopmans PP, Hekster YA. Carbamazepine–indinavir interaction causes antiretroviral therapy failure. Ann Pharmacother 2000; 34: 46570.
  • 62
    Liedtke MD, Lockart SM, Rathbun RC. Anticonvulsant and antiretroviral interactions. Ann Pharmacother 2004; 38: 4829.
  • 63
    Flockart DA, Tanus-Santos JE. Implications of cytochrome P450 interactions when prescribing medication for hypertension. Arch Intern Med 2002; 162: 40512.
  • 64
    Tartara A, Galimberti CA, Manni R, Parietti L, Zucca C, Baasch H, Caresia L, Muck W, Barzaghi N, Gatti G, Perucca E. Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine bioavailability in epileptic patients. Br J Clin Pharmacol 1991; 32: 33540.
  • 65
    Michelucci R, Cipolla G, Passarelli D, Gatti G, Ochan M, Heinig R, Tassinari CA, Perucca E. Reduced plasma nisoldipine concentrations in phenytoin-treated patients with epilepsy. Epilepsia 1996; 37: 110710.
  • 66
    Spina E, Perucca E. Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. Epilepsia 2002; 43 (Suppl. 2): 3744.
  • 67
    DeToledo JC, Haddad H, Ramsey SE. Status epilepticus associated with the combination of valproic acid and clomipramine. Ther Drug Monit 1997; 19: 713.
  • 68
    Soriano SG, Martyn JA. Antiepileptic-induced resistance to neuromuscular blockers: mechanisms and clinical significance. Clin Pharmacokinet 2004; 43: 7181.
  • 69
    Krauss GL, Brandt J, Campbell M, Plate C, Summerfield M. Antiepileptic medications and oral contraceptive interactions. A national survey of neurologists and obstetricians. Neurology 1996; 46: 15349.
  • 70
    Crawford P, Lee P. Gender difference in the management of epilepsy—what women are hearing. Seizure 1999; 8: 1359.
  • 71
    Doose DR, Wang SS, Padmanabham M, Schwabe S, Jacobs D, Bialer M. The effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethisterone and ethinyl estradiol in healthy obese and nonobese female subjects. Epilepsia 2003; 44: 5409.
  • 72
    Rosenfeld WE, Doose DR, Walker SA, Nayak RK. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethisterone and ethinyl estradiol in patients with epilepsy. Epilepsia 1997; 38: 31723.
  • 73
    Crawford P, Chadwick DJ, Maryin C, Tjia J, Back DJ, Orme M. The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids. Br J Clin Pharmacol 1990; 30: 8926.
  • 74
    Bounds B, Guillebaud. Observational series on women using the contraceptive Mirena concurrently with anti-epileptic and other enzyme-inducing drugs. J Fam Plann Reprod Health Care 2002; 28: 7880.
  • 75
    Herzog AG, Farina EL, Blum AS. Serum valproate levels with oral contraceptive use. Epilepsia 2005; 46: 9701.
  • 76
    Harder S, Thurmann P. Clinically important drug interactions with anticoagulants. An update. Clin Pharmacokin 1996; 30: 41644.
  • 77
    Cropp JS, Bussey HI. A review of enzyme induction of warfarin metabolism with recommendations for patient management. Pharmacotherapy 1997; 17: 91728.
  • 78
    Breckenridge A. Drug interactions with oral anticoagulants. BMJ 1974; 2: 397400.
  • 79
    McDonald MG, Robinson DS. Clinical observations of possible barbiturate interference with anticoagulation. J Am Med Ass 1968; 204: 959.
  • 80
    Hassan Y, Awaisu A, Aziz NA, Ismail O. The complexity of achieving anticoagulation control in the face of warfarin–phenytoin interaction: an Asian case report. Pharm World Sci 2005; 27: 169.
  • 81
    Stephen LJ. Drug treatment of epilepsy in elderly people: focus on valproic acid. Drugs Aging 2003; 20: 14152.